Nephrotoxicity is increased in some patients by the concurrent use of
ciclosporin and amikacin, gentamicin or tobramycin. This interaction would be expected with all systemic
aminoglycosides.
The concurrent use of
ciclosporin and
aminoglycosides should only be undertaken if the
clinical benefit outweighs the risk of
renal damage. Close monitoring of
renal function and aminoglycoside levels is required.